New insider Banjak Marc claimed ownership of 1,875 shares (SEC Form 3)
$IBIO
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 08/14/2024 |
3. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock (RSU) | 1,875(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | 02/21/2022 | 02/21/2032 | Common Stock | 800(2) | $170.4 | D | |
| Stock Option (Right to Buy) | 08/29/2022 | 08/29/2032 | Common Stock | 600(2) | $141.2 | D | |
| Stock Option (Right to Buy) | 08/23/2023 | 08/23/2033 | Common Stock | 3,000(2) | $6.92 | D | |
| Stock Option (Right to Buy) | 04/25/2024 | 04/25/2034 | Common Stock | 29,000(2) | $1.72 | D | |
| Stock Option (Right to Buy) | 05/09/2024 | 05/09/2034 | Common Stock | 55,000(3) | $1.88 | D | |
| Explanation of Responses: |
| 1. Consists of 1,875 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 1,875 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 1,875 RSUs vested pro rata quarterly over 12 months and consists of 468 RSUs which fully vested on June 30, 2023, 469 RSUs which fully vested on September 30, 2023, 469 RSUs which fully vested on December 31, 2023 and 469 RSUs which fully vested on March 31, 2024. |
| 2. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by the Company. |
| 3. These options vest in equal amounts on a quarterly basis over a 3-year period commencing on the date of grant, provided that the reporting person remains employed by the Company. |
| /s/ Marc Banjak | 08/14/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||